

1 **Title:**

2 **Vaccination mitigates climate-driven disruptions to malaria control**

3  
4 **Authors**

5 Benjamin L. Rice<sup>1\*</sup>, Estelle Raobson<sup>2,3</sup>, Sylviane Miharisoa<sup>4</sup>, Mahery Rebalaha<sup>5,6</sup>, Joseph Lewinski<sup>6</sup>,  
6 Hanitriniaina Raharinirina<sup>2</sup>, Bryan Greenhouse<sup>7</sup>, Christopher D. Golden<sup>5,8</sup>, Gabriel A. Vecchi<sup>9,10</sup>, Amy  
7 Wesolowski<sup>11</sup>, Bryan Grenfell<sup>1,12</sup>, C. Jessica E. Metcalf<sup>1,12</sup>

8  
9 **Affiliations**

- 10 1. Department of Ecology and Evolutionary Biology, Princeton University; Princeton, NJ, USA.  
11 2. Mention Zoologie et Biodiversité Animale, University of Antananarivo; Antananarivo,  
12 Madagascar.  
13 3. Association Vahatra; Antananarivo, Madagascar.  
14 4. Institut Pasteur de Madagascar; Antananarivo, Madagascar.  
15 5. Madagascar Health and Environmental Research (MAHERY); Maroantsetra, Madagascar.  
16 6. Multisectoral Malaria Project, Catholic Relief Services; Baltimore, MD, USA.  
17 7. EPPICenter Program, Division of HIV, Infectious Diseases, and Global Medicine, Department of  
18 Medicine, University of California San Francisco; San Francisco, CA, USA.  
19 8. Department of Nutrition, Harvard TH Chan School of Public Health; Boston, MA, USA.  
20 9. Department of Geosciences, Princeton University; NJ, USA.  
21 10. High Meadows Environmental Institute, Princeton University; NJ, USA.  
22 11. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; Baltimore,  
23 MD, USA.  
24 12. Princeton School of Public and International Affairs, Princeton University; Princeton, NJ, USA.

25  
26 \*Corresponding author. Email: [b.rice@princeton.edu](mailto:b.rice@princeton.edu)

27  
28  
29 **Abstract**

30 Increasingly extreme weather events in high malaria burden areas threaten progress to disease  
31 control targets. Yet, data on the impact of these events on control programs remain rare. Using  
32 unique data from Madagascar, we estimate high rates of infection in the wake of two major  
33 tropical cyclones. Evidence that infection rebounds rapidly during gaps in interventions indicates  
34 maintaining continuity of coverage is crucial to limiting burden. Relative to other interventions,  
35 recently available malaria vaccines have a longer duration of protection, with the potential to  
36 address interruptions in prevention deployment. Evaluating this use case, we quantify the  
37 reduction in symptomatic infections expected for a range of vaccination scenarios. We find long-  
38 lasting interventions such as vaccination are a key mitigation measure against climatic  
39 disruptions to disease control.

## 46 **Main Text**

47 Malaria remains a major global health challenge (1, 2). Much work has investigated how the  
48 coincident challenge of climate change threatens progress to malaria control (1). Rising  
49 temperatures modify mosquito vector dynamics (3–5), altering infection risk (6, 7), but these  
50 impacts are often focused in low burden areas at the altitudinal and latitudinal margins of malaria  
51 transmission (8–10). By contrast, extreme weather events, with some types likely to increase in  
52 frequency or severity due to climate change (11–14), disrupt public health efforts (15–19),  
53 including in areas where the burden of malaria is concentrated. Data on the impact of climate-  
54 related disasters on malaria infection remain rare (18, 20, 21), despite high rates of exposure to  
55 such events in malaria endemic settings and the clear importance of disruptions amidst the  
56 changing landscape of malaria control activities.

57 In response to stalled progress in malaria control in high burden countries and the development  
58 of new treatment and prevention tools (1), the World Health Organization (WHO) and national  
59 malaria control programs are preparing the large-scale deployment of new interventions. These  
60 include scaling the mass distribution of antimalarial chemoprophylaxis and treatment (e.g.,  
61 seasonal or perennial malaria chemoprophylaxis, SMC, PMC), and vaccination (see **Table S1**).  
62 Continuity is important to all of these interventions, as their effectiveness erodes over time, thus  
63 requiring regular re-administration. Extreme weather events threaten that continuity by delaying  
64 or degrading public health activities (18). Understanding the barrier this poses to achieving  
65 malaria control targets requires detailed data on infection risk during periods of likely disruption.  
66 However, limitations in surveillance systems make such data rare.

67 Tropical cyclones are an example of extreme weather events repeatedly shown to disrupt health  
68 systems for weeks to months following the event (21–26). Madagascar, our focus here, is subject  
69 to regular tropical cyclones (**Figure 1**), resulting in widespread destruction, population  
70 displacement, and damage to healthcare-related infrastructure (**Data S1**). We leverage a unique  
71 dataset comprising repeated measures of malaria infection status surrounding cyclone events ( $n =$   
72 20,718 observations) to develop a platform to explore the spectrum of recommended  
73 interventions and their robustness under climate change.

74

## 75 **Results**

### 76 ***1. High rates of exposure to cyclones and malaria infection***


#### 77 *1.1 Cyclone frequency and disruptive effect in Madagascar*

78 Cyclone frequency and severity has increased in the southern Indian Ocean (27, 28) with storms  
79 in Madagascar causing repeated humanitarian emergencies in recent years. Cyclones Batsirai and  
80 Freddy destroyed over 300 health facilities (29–32) and resulted in an estimated 112,115 and  
81 290,000 people in need of immediate humanitarian assistance in 2022 and 2023, respectively  
82 (33) (**Figure 1D**). Excess rainfall for Cyclone Batsirai was made more likely by increased


83 greenhouse gas and changes in aerosol emission per climate attribution studies (34). Our study  
84 site, Mananjary district, is located on the east coast of Madagascar, a moderate to high malaria  
85 transmission area.

86  
87


88 **Figure 1: The scale of cyclone-malaria interactions globally and in Madagascar**




89



90  
91 **Figure 1A:** Blue lines show cyclone tracks from IBTrACS for all storms since 1980 (35, 36). Malaria incidence  
92 estimates are from the Malaria Atlas Project (37). Inset: Intensity for the 1705 recorded storms impacting currently  
93 malaria endemic countries since 1980 (defined as storm center approaching within 60 nautical miles of landfall). For  
94 boxplots, the midline shows the median number of storms in the period 1980-2023, lower and upper hinges  
95 correspond to the 25th and 75th percentiles and whiskers extend 1.5 times the interquartile range. Points show the  
96 number of storms for a given year, jittered for visibility. Categories follow the Saffir-Simpson wind scale for the  
97 maximum wind speed observed within 60 nautical miles of landfall: Tropical Depression (TD), Tropical Storm (TS),  
98 Hurricane Category 1-5 equivalent (H1-H5), or no wind speed data available (ND).  
99



100



101

102

103

104

105

106


107

108


109

**Figure 1B:** Malaria burden versus cyclone exposure at the national scale. Bivariate fill color (38) shows average annual person-days of exposure to tropical cyclones from 2002-2019 (39) vs reported national malaria incidence (40). Countries with no reported malaria cases or cyclone exposure are in gray. Madagascar circled for reference. Inset: Malaria incidence vs the number of tropical cyclones since 1980 passing within a 60 nautical mile buffer of coastline (from IBTrACS), on a log-10 scale. Points are labeled by three-letter country codes. Among high malaria burden countries (annual incidence > 100 per 1000 population), Madagascar (MDG, circled) and Mozambique (MOZ) have the highest observed cyclone frequencies, followed by the Solomon Islands (SLB) and Papua New Guinea (PNG).





110  
111 **Figure 1C:** Tropical cyclone tracks in Africa colored by year of the storm. Inset: Tropical storm activity is highest  
112 in southeast Africa with over 47.9% of impacts in Africa overall contributed by Madagascar and Mozambique.  
113



114  
115 **Figure 1D:** Tropical cyclone activity for Madagascar since 1980 with the study district, Mananjary, outlined. Tracks  
116 show the estimated path of the storm center, with those passing within 60 nautical miles (111.1 km) of the  
117 Mananjary district shown in blue (others in gray). Two examples of recent cyclones impacting the Mananjary  
118 district, Cyclone Batsirai and Cyclone Freddy, are highlighted with estimated wind speed (data from IBTrACS) and  
119 estimates of the number of individuals requiring humanitarian assistance (data from EM-DAT).  
120

121 *1.2 Characterizing malaria infection rates*


122 We characterize rates of malaria infection from a longitudinal cohort study of a random sample  
123 of 500 households (2954 individuals, all ages) from 10 localities (**Figure 2A**). Repeated  
124 sampling of malaria infection status by rapid diagnostic test (RDT) was performed for the period  
125 July 2021-April 2023 (mean number of samples per enrolled individual = 7.7, median = 9)  
126 (**Figure S1**). The interval between samples was short (mean = 57.4 days, median = 52 days)  
127 relative to the duration of an untreated *P. falciparum* infection (approx. 180 days (41, 42)),  
128 indicating a low probability of natural infection clearance prior to the next sample. All  
129 individuals positive for malaria were treated to clear infections, allowing estimates of rates of  
130 infection and re-infection (see methods). During the course of the study, the area was impacted  
131 by Cyclone Batsirai (February 5, 2022) and Cyclone Freddy (February 21, 2023), providing  
132 estimates of malaria infection rates in the period before and for the 2 months after each event.

133

134

135


**Figure 2: Malaria infection rates following tropical cyclones in southeast Madagascar**




136

137 **Figure 2A:** Sampling locations for cohort study sites (MNJ.01-MNJ.10, ordered from north to south). Location of  
138 the Mananjary urban area, the capital of the Mananjary district, shown with a square. District boundary shown in  
139 white, elevation data from the Copernicus Global Digital Elevation Model (43).

140



141  
 142 **Figure 2B:** Raw malaria infection observations by rapid diagnostic test (RDT) by individual for the 10 follow-up  
 143 sampling time points (T01-T10) for the 10 sample localities in Mananjary District, Madagascar (MNJ.01-MNJ.10).  
 144 For visualization, each row is an individual (individuals with >50% of attendance at sampling time points shown)  
 145 with a random subsample of 100 individuals shown for each locality (full data in supplement). Inset: An overview of  
 146 sampling methods. RDT positive individuals are treated to clear infections and estimate time to re-infection. Some  
 147 infections are uncounted due a false negative RDT result (shown as circles with black outline and red fill).




148  
 149 **Figure 2C:** Expected proportion of individuals infected in one month by site and age category (young children = 0-  
 150 5y, school-aged children = 6-13y, teenagers = 14-19y, adults = 20+y). Sites are ordered by infection rate.

151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163

### 1.3 Malaria infection results: Force of infection and exposure following cyclones

We derive estimates of the force of infection (FOI) by age and season from ten follow-up sampling time points (see methods) (**Figure 2B**). FOI peaked for school-aged children (**Figure S2**), consistent with the higher frequency of infection commonly observed in this group (e.g., (44)). Transmission fluctuated seasonally, with the percentage of school-aged children expected to be infected within a month ranging, by site, from 0.8-9.1% in October to 4.9-44.3% in May (**Figure 2C**). At the higher FOI sites (e.g., MNJ.01, MNJ.08, MNJ.09, MNJ.10), we estimate 13.5-35.6% of younger children and 20.0-49.1% of school aged children were exposed to malaria infection in the 2 months following Cyclones Batsirai and Freddy (**Figure 2D**). Equipped with these empirically derived estimates of the scale of the rate of infection, we can evaluate the potential impacts of disruptions to malaria control programs during cyclone season.



164  
165 **Figure 2D:** Estimated probability of an uninfected individual from a standard household becoming infected by  
166 malaria after Cyclone Batsirai (February 5, 2022) and Cyclone Freddy (February 21, 2023) at study sites in  
167 Mananjary district, Madagascar.  
168

169

## 2. Malaria incidence is sensitive to brief disruptions in control

### 2.1 Supplemental malaria interventions in the context of disruption

172 Current operational plans for high malaria burden countries, including Madagascar (45),  
173 recommend implementing or expanding interventions using anti-malaria drugs to reduce burden



174 in targeted populations, as a supplement to existing base activities (i.e., bednet distribution).  
175 Approaches use the regular administration of either a standard first-line antimalarial with a short  
176 half-life (protective against reinfection for 13-15 days (46)) to clear existing infections (mass  
177 drug administration, MDA, or mass testing and treatment, MTaT) or a longer lasting antimalarial  
178 (protective for 21-42 days (47, 48)) to also prevent new infections (seasonal or perennial malaria  
179 chemoprophylaxis, SMC, PMC, or intermittent preventive treatment of malaria in pregnancy,  
180 IPTp) (see **Table S1**).

## 181 *2.2 Consequences of temporal gaps in coverage*

182 We explore the deployment of each of these supplemental interventions across the observed  
183 range of FOIs, introducing delays to follow-up administration rounds at different points along a  
184 seasonal cycle (see methods). Following the cessation of drug administration, protection decays  
185 at a rate determined by the drug half-life, and infections accumulate at a rate determined by the  
186 FOI for that locality, age group, and seasonal period (**Figure 3A**). Historical cyclone data for  
187 Madagascar indicates the time interval with the highest risk for storm impact occurs between  
188 January-April, contributing 81.8% of recorded tropical cyclones (**Figure 3B**). For a disruption  
189 that results in prophylactic protection ceasing on March 1st, we estimate 5.3-11.9% of younger  
190 children and 8.0-17.6% of school aged children are infected by day 20 in high FOI sites. This  
191 indicates that the temporary gaps in prophylaxis administration likely in the aftermath of extreme  
192 weather events are a major challenge for control programs aiming to minimize burden (e.g.,  
193 maintain infection below a 1% or 10% threshold) among vulnerable children.


## 194 *2.3 Incidence results are robust to variation in the force of infection*

195 Our initial estimates of FOI indicate that prevalence rebounds rapidly when drug-based treatment  
196 and prevention coverage ceases (e.g., reaching 10% for school-aged children within 8-92 days by  
197 site). Future changes to malaria transmission dynamics or uncertainty in initial estimation of FOI  
198 may result in variation in the rate of rebound. For example, undercounting infected hosts due to  
199 imperfect RDT sensitivity will result in an underestimation of FOI (**Figure S3**). To account for  
200 this, we evaluate a range of FOI scenarios (**Figure 3C**). Increasing FOI results in prevalence  
201 reaching the threshold prevalence level sooner (e.g., for school aged children, reaching 10%  
202 prevalence 3-31 days sooner for a 50% increase in FOI), demonstrating that rapid rebounds in  
203 prevalence are robust to RDT sensitivity or other sources of underestimation. Alternatively, FOI  
204 could be decreased by reductions in the intensity of transmission achieved by intervention rounds  
205 prior to the disruption event. However, even in optimistic scenarios where earlier rounds of drug  
206 administration substantially reduce transmission rates, prevalence rebounds are only slightly  
207 delayed at high FOI sites (e.g., by 8-9 days for a 50% decrease in FOI for sites MNJ.01 and  
208 MNJ.10). These data suggest chemoprevention-based intervention regimes with currently  
209 available drugs are of limited efficacy in maintaining a low prevalence of infection in the face of  
210 climate-driven disruptions for the FOI ranges likely in moderate to high transmission settings.


211




212 **Figure 3: Modeled increase in malaria infection due to interrupted drug administration**



213  
 214 **Figure 3A:** Schematic for estimating the risk of malaria infection over time as a function of the force of infection  
 215 (FOI) and the rate of decay of prophylactic protection. For example, an interruption to the re-administration of a  
 216 short and long half-life chemoprevention drug is caused by a tropical cyclone (image source: NASA, Cyclone  
 217 Batsirai, February 2, 2022).  
 218



219  
 220 **Figure 3B:** Left: Calendar date of recorded tropical storms impacting Madagascar since 1980. Right: The  
 221 cumulative probability of infection (i.e., the proportion of the susceptible population expected to be infected)  
 222 for a 31-day interval beginning on that day, shown for school aged children (13 years of age). Differences among sites are  
 223 shown as rings.



224  
 225 **Figure 3C:** Time until infection reaches a target prevalence versus the force of infection (FOI). A threshold of 10%  
 226 prevalence is chosen as an example, corresponding to the WHO-defined upper limit for a low malaria burden  
 227 setting. Baseline observed FOIs for March for the ten sampling localities in Mananjary district (shown with vertical  
 228 dotted line) are increased or decreased by 0-99% for each site for four exemplar age groups. For reference, the  
 229 dotted horizontal line shows 90 days (approx. 3 months), with the area under the horizontal line (outlined in red)  
 230 corresponding to scenarios where the FOI is such that an interruption in access to chemoprevention of that duration  
 231 results in infection exceeding the target threshold.


232

### 233 3. Vaccination under climate-driven disruption to control


#### 234 3.1 Modeling vaccination

235 An exciting shift for malaria control is the recent availability of anti-malarial vaccines. Uniquely,  
 236 vaccines have a substantially longer duration of protection (i.e., > 10 months (49, 50)) than  
 237 currently used chemoprophylaxis drugs and the time interval relevant for seasonal, climate-  
 238 driven disruptions such as tropical cyclones (i.e., 3-4 months). Additionally, vaccines using new  
 239 technology such as mRNA may improve upon the efficacy against clinical disease observed so  
 240 far for the recently authorized RTS,S (50-56%) (49) and R21 (68-75%) (50) vaccines. To  
 241 evaluate the potential of vaccines to reduce malaria burden under climate disruptions, we  
 242 quantify the reduction in burden under a range of scenarios of vaccine coverage, efficacy, and  
 243 symptomatic rates of infection (see methods) (Figure 4A). Symptomatic rates are obtained from  
 244 our cohort study where we find 37.0-53.2% of infections among children are associated with  
 245 observable symptoms (Figure S4), in line with previous estimates of asymptomatic infection  
 246 rates in moderate to high transmission settings (without vaccination) (51).


247 **Figure 4: Symptomatic malaria infection probabilities during disruption under a model of**  
 248 **vaccination**



249 **Figure 4A:** Probability tree of the outcomes of malaria infection under vaccination. Parameters on branches specify  
 250 the probability of either path at branching points. In the simplest analysis, the probability of symptomatic malaria  
 251 infection for an age group over a time period  $t$  is determined by the probability of infection,  $p(I) = 1 - e^{-\lambda t}$  where  $\lambda$  is  
 252 the force of infection, the vaccination coverage,  $v$ , the probability of symptoms given infection,  $s$ , and any protective  
 253 effect of vaccination,  $E$ . Vaccines may have efficacy against infection,  $E_i$ , or against symptoms,  $E_s$ . Note that when  
 254  $E_i$  is small, as is thought to be the case for currently available vaccines, the probability of infection is similar for  
 255 vaccinated,  $V$ , and unvaccinated,  $V'$ , individuals. When  $E_s$  is large, vaccinated individuals are unlikely to have  
 256 symptoms upon infection.  
 257



258 **Figure 4B:** The percent reduction in the number of expected symptomatic infections across a range of vaccine  
 259 efficacies. Without vaccination, the baseline probability of a symptomatic infection is  $s \cdot p(I)$ . Assuming  $E_i = 0$ , the  
 260 percent reduction in symptomatic infections due to vaccination can be expressed as  $(s \cdot p(I) - (S_v + S_{v'})) / (s \cdot p(I))$   
 261 which simplifies to  $v \cdot E_s$ . Estimates for the efficacy of the two currently available anti-malaria vaccines, RTS,S (49)  
 262 and R21 (50), are shown for example. The shaded quadrant shows the scenarios with sufficient efficacy and  
 263 coverage to observe a 50% reduction in symptomatic infections.  
 264  
 265



266  
 267 **Figure 4C:** For the targeted subpopulation (i.e., children), the number of symptomatic malaria infections averted by  
 268 vaccination with efficacy against symptoms  $E_s$ . Rows show results for four levels of infection rates, expressed as the  
 269 cumulative proportion of the population expected to be infected over the time interval considered. Columns show  
 270 results for three values for the probability with which infections become symptomatic.  
 271  
 272

273 *3.2 Vaccination has the potential to reduce malaria burden following extreme weather events*

274 When 70% of the targeted population has completed the full course for a vaccine with efficacy  
 275 68-75% (that reported for the R21 vaccine in phase 3 trials (50)) prior to the disruptive event, a  
 276 47.6-52.5% reduction in the expected proportion of symptomatic infections is expected (**Figure**  
 277 **4B**). This level of vaccine coverage is plausible given the coverage (approx. 70%) reported for  
 278 routine childhood immunization in the country (52, 53). Existing estimates of vaccine efficacy  
 279 are obtained on high background rates of access to and use of bednets and other vector control  
 280 interventions (54). Estimates of bednet usage in Madagascar are 70-80% on the east coast of  
 281 Madagascar (55) and at our study sites we estimate usage was 72.6-82.6% before and 69.4-  
 282 76.4% after the two cyclone events (**Figure S5**). The number of cases averted is dependent on  
 283 the infection rate and the symptomatic rate. Using the observed parameter values for the highest  
 284 force of infection site (MNJ.10) and 50-70% coverage with the R21 vaccine as an example, we  
 285 estimate, per 1000 children, a decrease from 135.1-193.5 symptomatic infections in the 2 months  
 286 following a February cyclone to 64.1-101.4 symptomatic infections under vaccination (with  
 287 45.9-101.6 cases averted, respectively) (**Figure 4C**).

288

289

290 *3.3 Vaccination results are robust to modest efficacy and coverage*

291 Vaccine completeness or timeliness may be imperfect for a fraction of the population, for  
292 example due to the timing of a child's birth relative to planned vaccination dates or missed  
293 vaccination rounds. Additionally, efficacy may wane in subsequent years (50). To account for  
294 this variation in the degree of protection we explore a range of proportions of partially protected  
295 individuals (**Figure S6**). We also explore a range of symptomatic infection probabilities,  
296 including scenarios where symptomatic infection becomes more probable as infection derived  
297 immunity declines under lower incidence (**Figure S7**). We find vaccination can lead to a  
298 substantial reduction (i.e., approx. 50%) in the frequency of symptomatic malaria infection  
299 during disaster aftermath, results that are robust to even moderate vaccine efficacy and  
300 reasonable vaccination coverage (**Figure 4B-C**).

301

302 **Discussion**

303 *1. Temporal gap-filling as a potential use case for malaria vaccination*

304 Leveraging a unique dataset from Madagascar, we demonstrate that discontinuities in protection  
305 against malaria are a critical threat to efforts to reduce burden. Extreme weather events are a  
306 challenge to maintaining continuity. Climate change amplifies the risk of some extreme weather  
307 events (56), including tropical cyclones (11), with potentially devastating consequences relevant  
308 for health (18). The role of the disruptions likely to result from climate-driven disasters, and the  
309 best options for response, have been neglected in the study of climate change and malaria.  
310 Vaccination, recently available for malaria, has the unique feature of a protective effect sufficient  
311 in duration to persist through disruptive events, such as cyclones and their aftermath. To date,  
312 assessments of the cost-effectiveness of vaccination, and priority areas for vaccine deployment,  
313 do not account for the additional benefit of long lasting protection, even when moderate, against  
314 disease in times of disruption. Our findings suggest a new use case for vaccines, the deployment  
315 of vaccination in areas vulnerable to climate-driven or other disruption.

316 *2. Limitations: Diagnostic uncertainty from reliance on RDTs and moderate vaccine efficacy*

317 Ideally, estimates of infection rate would be determined with highly sensitive diagnostics (e.g.,  
318 PCR) (51, 57). Here, as in many settings with limited access to advanced health infrastructure,  
319 diagnostic options were constrained to field-deployable, rapid diagnostics (e.g., RDTs). We  
320 developed a set of sensitivity analyses to allow inference under the expected diagnostic  
321 uncertainty, with general applicability to other settings reliant on RDTs for surveillance. While  
322 RDTs are likely to miss low parasitemia infections (58), the extent to which these contribute to  
323 clinical burden, the target for vaccination, is unclear (41, 59). Additionally, as described above,  
324 undercounting these infections minimally alters the magnitude of timing of infection rebound  
325 relevant for disaster response.



326 As malaria control programs prepare to scale up interventions to meet ambitious targets in  
327 coming years, investment across multiple control options must be evaluated (60). Benefits from  
328 covering any temporal gaps in drug administration present an important case for considering  
329 vaccination, even given current shortcomings. Limited vaccine efficacy and questions as to cost-  
330 effectiveness across varied settings (61–63), alongside their minimal transmission blocking  
331 activity, and restricted age range for which data are available (e.g., children < 4 years) mean that  
332 vaccines are unlikely to be deployed alone. Efforts that combine prevention approaches with  
333 different kinetics, even though they may appear redundant during periods without disturbance,  
334 are likely needed to mitigate the impact of extreme weather events. Such approaches could  
335 include reinforcement of vector control interventions such as bednets during periods of  
336 population displacement (64–66), strengthening health facilities to minimize damage (67, 68),  
337 and creative drug distribution approaches for prophylaxis that avoid dependence on storm-  
338 vulnerable infrastructure (for example, for intermittent preventive treatment during pregnancy,  
339 IPTp).

### 340 *3. The need for more research on attribution and disaggregating mechanisms of risk*

341 A limitation of our study is reliance on estimates of aggregate risk of infection following a  
342 climate event. A challenging but important task for future investigations will be to separate the  
343 proportion of risk attributable to background and seasonal trends from the direct and indirect  
344 impacts of an extreme weather event. We hypothesize tropical cyclones alter the risk of infection  
345 through multiple mechanisms such as flooding, population displacement, and destruction of  
346 housing and clinics (18, 21, 69), that interact to modify mosquito vector abundance, host  
347 exposure to infection, and access to and use of prevention and treatment. We find the overall  
348 magnitude of infection to be high, which will dictate the burden experienced during disaster  
349 aftermath and the likely response to control measure scenarios. Obtaining further resolution,  
350 however, is limited by difficulty in deriving expectations for a non-cyclone impacted year for the  
351 study area. This is due to the scarcity of long-term data with direct estimates of malaria infection  
352 rates and the high frequency of cyclones. Both cyclone seasons of the present study (2022 and  
353 2023) featured major storms and, at the national scale, Madagascar has experienced 48 cyclones  
354 with intensity at or greater than a category 1 hurricane in the 44 years since 1980. Additionally,  
355 storms will interact with multi-year changes in underlying drivers of malaria risk, such as  
356 periodic mass bednet campaigns, and any residual damage to infrastructure from previous years'  
357 storms. Despite these complexities around identifying a storm's possible impact on transmission  
358 potential, critically, any decline in the continuity of access to healthcare and the deployment of  
359 control measures will increase population exposure to transmission. As a result, data on total risk  
360 of infection following a climate event, even when the fraction attributable to the event is low or  
361 uncertain, will be valuable for planning and should be a priority for future surveillance efforts.

### 362 *4. Implications for disease control in an era of increasingly extreme weather*

363 The overwhelming majority of global malaria cases and deaths come from a subset of African  
364 countries (e.g., 20 African countries contribute 86% of global cases) (1). The context of stalled

365 progress in control efforts in these high burden settings, the broad effects of climate change, new  
366 recommendations for expanded chemoprevention, and the advent of vaccination create a new  
367 environment for malaria control. Health system and infrastructural disruptions in these high  
368 burden areas could be a major consequence of climate change for malaria. Continuity in public  
369 health efforts will be decisive for global efforts to reduce the burden of this pathogen. Severe  
370 tropical cyclones, a source of likely disturbance, have marked seasonality, making the timing of  
371 their impact predictable and enabling anticipatory interventions such as vaccination. Other forms  
372 of disturbance (e.g., civil conflict (70, 71)) may be less predictable in their timing, but could  
373 benefit from similar analyses. In addition to malaria, other infectious diseases subject to control  
374 regimes reliant on the regular distribution of drugs or vaccination may be vulnerable to climate-  
375 driven disruption (23, 72). This warrants increased attention on the interaction between climate  
376 and the continuity of public health access. Our data suggest, in the malaria and tropical cyclones  
377 case, vaccination – less sensitive to short term disruption – will be a key mitigation measure.

378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406

## 407 **Acknowledgements**

408 We thank the CRS Multisectoral Malaria Project staff for support and the CRS Madagascar office and  
409 Mananjary malaria project staff for assistance with data collection: Dr. Virginie Andreas Nambinina  
410 Ralisoa, Dr. Elanirina Andrianoelivololona, Elodie Mialinjaka Rabarijaona, Tahiniony Tonie Ludjette  
411 Rakotozafy, Johnson Rakotohasimbola, Juloce Lidovique Razafindrakoto, Hermann Raelison Paratoaly,  
412 Aymardine Flashe Kantomananjara, Simon Razafindrasoja, Arisoa Beatrice Marie Sandrine Nirry, and  
413 James Hazen. We thank the High Meadows Environmental Institute (HMEI) at Princeton University for  
414 support.

### 415 **Funding:**

416 CRS SCP4 Multisectoral Malaria Project (BLR, SM, MR)

417 The Falcon Award for Disease Elimination - The Climate Edit by the Global Institute for Disease  
418 Elimination (GLIDE) (BLR, MR)

419 The Ren Che Foundation and the AWS Impact Computing Project at the Harvard Data Science Initiative  
420 (HDSI) (CDG)

421 The High Meadows Environmental Institute (HMEI) at Princeton University (BLR, GAV, CJEM)

### 422 **Author contributions:**

423 Conceptualization: BLR, MR, JL, BG, CDG, AW, BG, CJEM

424 Methodology: BLR, BG, AW, BG, CJEM

425 Investigation: BLR, ER, SM, MR, HR

426 Visualization: BLR, BG, CJEM

427 Funding acquisition: BLR, MR, JL, CDG

428 Project administration: BLR, MR, JL

429 Writing – original draft: BLR, BG, CJEM

430 Writing – review & editing: BLR, ER, JL, GAV, AW, BG, CDG, CJEM

### 431 **Competing interests:**

432 Authors declare that they have no competing interests.

### 433 **Data and materials availability:**

434 All data are available in the main text or the supplementary materials. Code and data files are available at  
435 a github repository: [https://github.com/bennyrice/mananjary\\_cyclone\\_code](https://github.com/bennyrice/mananjary_cyclone_code)

436

437

438

439

440

441

442

443

444

## 445 **Supplementary Materials**

446

## 447 **Materials and Methods**

### 448 **1. Study area: Mananjary district, southeastern Madagascar**

449 Located in southeastern Madagascar, the Mananjary district (region Vatovavy) is a coastal district with  
450 perennial malaria transmission. The district extends approximately 60 km to the north and south of the  
451 district capital, the city of Mananjary (-21.22 S, 48.35 E) where the only hospitals in the district are  
452 located. As of 2018, 90.1% of the population of the district lives in rural *kaomina* (“communes”) (Institut  
453 National de la Statistique Madagascar).

454 From Malaria Indicator Surveys, malaria prevalence among children 5 years or younger in the east coast  
455 of Madagascar averaged 9-18% from 2011 to 2021 (55, 73–75), placing the district in the WHO defined  
456 moderate transmission stratum. In terms of seasonality, higher prevalence was estimated for December to  
457 May from re-analyses of health facility data (76, 77), with a peak around April (78). Few recent  
458 epidemiological studies with active sampling are available from the region, but prevalence among  
459 households (all ages) varied from 3-46% by locality in 2017 from cross-sectional prevalence surveys (44,  
460 79).

### 461 **2. Extreme weather event data**

462 Historical data on the occurrence of extreme weather events was sourced from the National Oceanic and  
463 Atmospheric Administration (NOAA) International Best Track Archive for Climate Stewardship  
464 (IBTrACS) data (accessed 21 February 2024) and EM-DAT from the Centre for Research on the  
465 Epidemiology of Disasters (CRED) (accessed 21 February 2024). See **Data S1** for the full list of weather  
466 events.

467 Search criteria were all storms where the eye passed within a 60 nautical mile (approx. 111 km) buffer of  
468 Madagascar’s coastline. This buffer was chosen because extreme rainfall and winds may extend across  
469 the diameter of a storm. Tropical cyclones are defined as systems with maximum sustained wind speeds >  
470 119 km/h, equivalent to a Category 1 Hurricane per the Saffir-Simpson scale used in the Atlantic basin.

### 471 **3. Longitudinal sampling**

#### 472 *3.1 Prospective cohort study*

473 A stratified random sample of 500 households evenly distributed among 10 rural sampling clusters  
474 (communities or *tanana*) were recruited and enrolled during a baseline sample in July-October 2021.  
475 Informed consent or assent was obtained for study participants prior to enrollment. Enrolled households  
476 were followed longitudinally for 10 follow-up sampling time points. Clusters were rural (defined as more  
477 than 5km from the Mananjary district capital) and approximately 10 km apart on average.

478 Study procedures received approval from the Institutional Review Board (IRB) of the Harvard T.H. Chan  
479 School of Public Health (IRB#21-0111), Comité d’Ethique de la Recherche Biomédicale (CERBM) at  
480 Ministère de la Santé Publique de Madagascar (N°019/MSANP/SG/AMM/CERBM 2021), the Mananjary  
481 district health office, local government authorities, and community leaders.

482 **Figure S1** shows the proportion of the cohort negative, positive, and unsampled by rapid diagnostic test  
483 (RDT) per time point. The participation rate, calculated as the percentage of enrolled individuals  
484 screened, ranged from 62.5-91.0% per time point. We consider individuals with visible bands for lactate  
485 dehydrogenase (LDH) or histidine rich protein 2 (HRP2) antigens as positive. The RDTs used were the  
486 AccessBio CareStart™ Pf/Pan RDT or Abbott Diagnostics Bioline™ Malaria Ag Pf/Pan RDT per  
487 manufacturer's protocol.

### 488 *3.2 Screening for malaria and symptoms*

489 All individuals in enrolled households were screened for malaria at approximately 2-month intervals  
490 (mean interval between samples = 57.4 days, median = 52 days,  $n = 20,718$  total observations). On site  
491 diagnosis by RDT was performed at the time of screening and a blood sample was collected on a dried  
492 blood spot (DBS) for later molecular confirmation. Individuals, or a surrogate for younger children, also  
493 completed a questionnaire on bednet usage and symptoms adapted from refs. (80, 81). Sensitivity  
494 analyses were performed to account for RDT sensitivity and specificity (**Figure S3**).

495 Individuals positive for malaria by RDT were offered treatment by an onsite physician with artemisinin-  
496 based combination therapy (ACT) using the standard first line treatment for Madagascar (artesunate  
497 amodiaquine, AS+AQ). To observe treatment adherence, at minimum the first dose of the three-day  
498 course of treatment was observed directly by the research team. Symptomatic individuals or individuals  
499 requesting a consultation were offered a consultation with an onsite physician.

### 500 *3.3. Accounting for RDT sensitivity and specificity*

501 Due to imperfect sensitivity and specificity for RDTs, false positive and false negative RDT results may  
502 bias inference of infection rates. From a previous study, an estimated 97% of infections in the east coast  
503 region of Madagascar are by *Plasmodium falciparum* and 88% of RDT positive infections were  
504 confirmed by molecular follow-up (82). In studies of diagnostic performance, RDT sensitivity and  
505 specificity was estimated to be approximately 80-90% (83, 84).

506 We use a binomial sampling approach to explore the effect of diagnostic error. We simulate 'false  
507 negatives' by drawing from a binomial distribution with probability  $1 - \text{sensitivity}$  such that a fraction of  
508 RDT negatives become positive. Likewise, we simulate 'false positives' by drawing from a binomial  
509 distribution with probability equal to the *specificity* such that a fraction of RDT positives become  
510 negative. **Figure S3** shows simulations over a range of sensitivity and specificity values, where we repeat  
511 the force of infection estimation methods (described in the following section) for 500 replicates. These  
512 results illustrate minimal bias across plausible ranges of sensitivity and specificity. When the proportion  
513 of positive tests is small, accounting for possible false negatives results in an increase in the expected  
514 proportion infected. For sites with a high proportion of positive tests (i.e., approximately 50%), false  
515 negatives and false positives are similarly likely such that the expected proportion infected is minimally  
516 changed.

## 517 **4. Estimating the force of infection**

518 The interval before infection probability reaches a given threshold will hinge on target prevalence and the  
519 rate at which individuals become reinfected. To evaluate this, we define  $\lambda$  as the force of infection, or rate  
520 at which susceptible individuals become infected. The catalytic model (85) then defines the probability of  
521 evading infection up until time  $t$  as:



522 
$$S(t) = \exp(-\lambda t)$$

523 and the probability of having been infected by time  $t$  (or cumulative density function of infection) is

524 
$$F(t) = 1 - \exp(-\lambda t)$$

525 For malaria, infected individuals are susceptible to reinfection. The rate at which this occurs within the  
526 time interval of interest will be negligible when the force of infection is low and/or the time interval  
527 considered is short, estimated to be the case here (e.g., within 1-2 months). We consequently proceed with  
528 the estimates based on  $F(t)$ .

529 Because no evidence of resistance to ACT antimalarials has been reported to date from Madagascar, we  
530 assume the clearance rate of asexual and sexual stages of the parasite to be high. Given our direct  
531 observation of the early doses of anti-malarial treatment for infected individuals, we assume adherence to  
532 the treatment course is high and successful clearance of parasite infections following treatment. Thus for  
533 individuals positive at  $t_i$  and  $t_{i+1}$  we assume that a new infection has occurred over the time interval.

534 The force of infection may vary according to time-invariant covariates such as geographic site, and  
535 individual age (which can be considered approximately time-invariant at least over the time-scales  
536 considered). We can fit these quantities using a generalized linear model fitted with a binomial likelihood  
537 using a complementary log-log link, such that if  $\pi_i$  is the probability of being infected over interval  $i$ , the  
538 link function is provided by  $\eta_i = \log(-\log(1 - \pi_i))$ . The cumulative density function can then be  
539 expressed as:  $F(\eta_i) = 1 - \exp(-\exp(\eta_i))$  from which it can be deduced that the link function must  
540 take the form  $\eta_i = \beta X_i + \log(t)$  where  $\beta$  is a vector of coefficients, and  $X_i$  is the corresponding design  
541 matrix of covariates for interval  $i$ . Introducing this back into the cumulative density function yields

542 
$$F(t) = 1 - \exp(-\exp(\beta X_i + \log(t))) = 1 - \exp(-(\beta X_i)),$$

543 indicating that the force of infection is defined by:  $(\beta X_i)$ , as desired (86).

544 To additionally capture seasonal fluctuations in the force of infection (by their nature time-varying), we  
545 can introduce covariates reflecting the number of days each individual at each measurement was exposed  
546 to different seasons of transmission (e.g., days in each month); and we can additionally introduce smooth  
547 terms to capture non-linear patterns. The extended force of infection is then provided by:

548 
$$(\alpha_{site,i} + s(age_i) + \gamma_1 M_{1,i} + \gamma_2 M_{2,i} + \gamma_3 M_{3,i} + \dots)$$

549 Where the parameter  $\alpha$  takes a different value for each of the ten study sites;  $s(age_i)$  indicates a  
550 smoothed pattern across age,  $M_{j,i}$  reflects the number of days an individual  $i$  was exposed to the  $j^{th}$   
551 month of the year, with  $\gamma_j$  the corresponding parameter converting this into effects on the force of  
552 infection. Finally, we also include a random effect for household, as there was evidence of consistent  
553 effects across households. The final expression for the force of infection is thus:

554 
$$(\alpha_{site,i} + s(age_i) + \gamma_1 M_{1,i} + \gamma_2 M_{2,i} + \gamma_3 M_{3,i} + \dots + H_i)$$

555 Where  $H_i$  corresponds to the random effect mapping the household of individual  $i$ .

## 556 **5. Exploring the consequences of disruptions during intervention rollout**

557 To explore the deployment of new mass chemoprevention and chemotherapy interventions, we simulate  
558 the early phases of these interventions, when the program is building towards, but has not yet, interrupted

559 transmission. As a result, ongoing transmission results in the reaccumulation of infections, at a rate  
560 determined by the force of infection, following each intervention round until transmission is interrupted  
561 (i.e., force of infection approaches 0). We first investigate the return time, which we define as the  
562 maximum time interval between intervention rounds for a given force of infection where malaria  
563 prevalence is maintained below a chosen target level in the targeted population (see supplementary  
564 methods for full details).

565 The required program return time  $\Delta_c$  necessary to maintain prevalence below a chosen threshold  $z$  is  
566 defined by:

567 
$$\Delta_c = \frac{-\log(1-z)}{\lambda}$$

568 The estimated force of infection captures the rate at which individuals become infected, and interventions  
569 occur at intervals of  $\Delta$  days, and clear  $p_t$  percent of infections. Conservatively, we assume clearance for  
570 treated individuals to be 100% such that treatment successfully reduces infectiousness and treated  
571 individuals do not participate in transmission. This is supported by the lack of evidence of resistance to  
572 ACTs in Madagascar to date and evidence ACTs clear gametocytes (87). Subsequent to this intervention,  
573 mosquito vectors infected with parasites prior to the intervention or from contact with subsets of the  
574 population not covered by the initial round serve as a reservoir for infection. Thus ‘cleared’ hosts start to  
575 become infected again from continued exposure. The longer the interval  $\Delta$ , the higher the prevalence of  
576 malaria reached within the target population.

577 We initially make no assumptions about feedbacks associated with transmission, and additionally  
578 disregard recovery without treatment, since time intervals to recovery are typically long. Supporting this,  
579 published estimates of the distribution of duration of untreated *P. falciparum* infections (mean duration  
580 approximately 180 days (41, 42)) indicate that the probability of recovery without treatment between our  
581 longitudinal samples (mean sampling interval 57 days) and during a disruption interval (e.g., 2 months)  
582 are very low.

## 583 **6. Simulating additional control activities: Prophylaxis and vaccination**

584 In addition to a primary intervention where a round of standard first line antimalarials (e.g., ACTs) is  
585 applied to clear existing infections, various interventions that prolong the duration of protection may be  
586 considered, from drug combinations with a longer prophylactic period to vaccination.

### 587 *6.1 Mass drug administration with longer lasting chemoprevention*

588 Including a longer-lived antimalarial (e.g., sulphadoxine-pyrimethamine, SP, or dihydroartemisinin-  
589 piperaquine, DP) can prevent reinfection for the duration of effective prophylaxis. We define the mean  
590 duration of prophylaxis as  $D$ . We first consider a mass drug administration (MDA) scenario where all  
591 individuals, regardless of infection status, are given the ACT treatment paired with a prophylactic. When  
592 used to prevent reinfection for clinical cases this has been termed post-discharge malaria prophylaxis  
593 (PDMC). We also consider application in a mass test and treat (MTaT) activity where only individuals  
594 identified as positive for malaria infection receive the chemoprevention (see **Table S1** for definitions).

595 Because the drugs likely to be used in PDMC, MDA, and MTA activity are the same as those for  
596 seasonal malaria chemoprevention (SMC) and intermittent preventive treatment (IPT), and thus have the  
597 same duration of protection, the return time for all can be modeled as  $D + \Delta_c$ .

598

599 **Table S1: World Health Organization assessed drug-based malaria interventions**

Intervention	Definition
Mass Drug Administration (MDA)	Presumptive treatment of a large proportion of the population. In the simplest form, performed with a standard first-line anti-malarial (e.g., ACTs in Africa). <i>Aliases and derivatives:</i> Equivalent to MTaT when combined with diagnostic screening prior to treatment. Termed targeted drug administration (TDA) when applied to a selected subpopulation and reactive drug administration (RDA) when performed reactively for an observed infection cluster.
Post Discharge Malaria Chemoprevention (PDMC)	Addition of a longer lasting antimalarial (e.g., SP) for a prophylactic effect for treated individuals. <i>Aliases and derivatives:</i> If applied proactively for a season or year, equivalent to SMC/PMC/IPT
Mass Test and Treat (MTaT)	Testing, regardless of symptoms, a large proportion of the population and providing treatment for those testing positive. <i>Aliases and derivatives:</i> Sometimes termed Mass Screen and Treat (MSaT); targeted test and treat (TTaT) when applied to a selected subpopulation.
Intermittent Preventive Treatment (IPT)	The regular (e.g., monthly) administration of a curative antimalarial dose to curtail infections and prevent new infections. <i>Aliases and derivatives:</i> Often targeted to pregnant women (IPTp) and infants (IPTi). Equivalent to SMC/PMC.
Seasonal/Perennial Malaria Chemoprophylaxis (SMC/PMC)	Equivalent to IPT, the use of a full treatment course of antimalarials at regular intervals to reduce the risk of malaria infection. Recently recommended for scale up to more geographic areas and children over 5. <i>Aliases and derivatives:</i> SMC when targeted to the season with high transmission, PMC when year-round.

600

601

602 *6.2 Vaccination*

603 Vaccination with the currently available antimalarial vaccines may provide a benefit in reducing clinical  
 604 cases when providing access to treatment or chemoprevention is unlikely. We use estimates of the  
 605 efficacy of antimalarial vaccines against clinical malaria reported from clinical trials for the RTS,S  
 606 (approx. 55%) (49) and R21 vaccines (approx. 75%) (54, 88).

607 In the simplest analysis, the expected number of clinical cases results from the rate of exposure,  $\lambda$ , giving  
 608 the probability of being infected over an interval, and the probability of infection being asymptomatic ( $a$ )  
 609 or symptomatic ( $s = 1 - a$ ). Given no data on efficacy against infection ( $E_i$ ) for currently approved  
 610 vaccines, we conservatively assume  $E_i = 0$ . For a proportion,  $v$ , of children fully vaccinated at the  
 611 beginning of cyclone season, with a vaccine of efficacy of  $E_s$  (defined as reduction in probability of  
 612 symptomatic malaria), we estimate the probability of symptomatic infection among children over an  
 613 interval of length  $t$  following cessation of intervention due to a disruption:

614 
$$\text{Pr}(\text{symptomatic infection}) = v \times (1 - e^{-\lambda t}) \times (1 - E_i) \times s \times (1 - E_s) + (1 - v) \times (1 - e^{-\lambda t}) \times s$$

615 See **Table S2** for parameter definitions and estimates.

616

617 **Table S2. Parameter definitions used in vaccination modeling**

Parameter	Definition	Range
$1 - e^{-\lambda t}$	Proportion of uninfected individuals that test positive during interval $t$	0.01-1.0
$v$	Vaccination coverage	0-100%
$s$	Proportion of infected individuals reporting symptoms	0.1-1.0
$E_s$	Efficacy against symptomatic infection for vaccination	0-100%

618

619

620

621

622

623

624

625

626

627

628

629

630

631



632

633

634

635 **Supporting Information**


636 **Figure S1. Sampling for the Mananjary malaria cohort study**



638  
 639 **1A:** The proportion of enrolled individuals unsampled, negative, or positive by rapid diagnostic test (RDT) per time  
 640 point from baseline (T0) to final sample (T10) (all sites combined). **1B:** Distribution of the number of observations  
 641 per individual (site code colors and order follow Figure 2C). **1C:** Distribution of the interval in days between  
 642 samples.



643 **Figure S2. Force of infection (FOI) by age**



644  
645 Observed variation in the force of infection by age for the 10 sample sites in Mananjary district, Madagascar (site  
646 code colors and order follow Figure 2C). Data shown for the month of January.

647

648

649

650

651

652

653

654

655

656


657

658

659

660


661 **Figure S3. Accounting for imperfect RDT diagnostic accuracy**



662 From 500 simulated trials, the force of infection (FOI) per day for a given sensitivity and specificity. Sites are  
663 ordered from lowest to highest observed rate of infection. Dashed vertical lines show the mean FOI from 500  
664 simulations. For low infection sites (e.g., Sites MNJ.06 and MNJ.04, shown at top left), reduced sensitivity increases  
665 estimates of FOI (e.g., FOI increases from an initial estimate  $6.3 \times 10^{-4}$  to a mean estimate of  $2.7 \times 10^{-3}$  for  
666 sensitivity and specificity = 90%). This indicates for low infection rate sites, our estimates for the probability of  
667 infection over a time interval are conservative, with false negative rapid diagnostic tests contributing to a higher  
668 probability of infection. For high infection sites (e.g., Sites MNJ.01 and MNJ.10, shown at bottom right) estimates  
669 of FOI are relatively invariant across the range of sensitivity and specificity values explored. False negatives and  
670 false positives largely offset such that the initial FOI estimate  $7.19 \times 10^{-3}$  is similar to the mean estimate ( $7.16 \times 10^{-3}$ )  
671 from the 500 simulated trials with sensitivity and specificity at 90%.  
672

673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683


684 **Figure S4. Symptomatic rates of infection by survey recall**



685  
686 The percent of rapid diagnostic test (RDT) positive individuals reporting any fever within the last two weeks of  
687 screening. Error bars show the 95% confidence intervals using the Clopper and Pearson (1934) method as  
688 implemented in the R binom.test function.

689  
690  
691  
692  
693  
694  
695  
696

697 **Figure S5. Bednet usage by survey recall**



698

699 The proportion of individuals reporting sleeping under a bednet in the last 24 hours and if reporting bednet was  
 700 damaged (due to holes, tears, or other damage). To the right, change in the proportion of individuals reporting not  
 701 using a bednet for sampling time points before and after two cyclones. Error bars show the 95% confidence intervals  
 702 using the Clopper and Pearson (1934) method as implemented in the R `binom.test` function.

703

704

705

706

707

708

709

710


711

712


713

714

715 **Figure S6. Simulating partial vaccination**



716




717

718 Top: Probability tree of the outcomes of malaria infection under partial vaccination. From the probability tree in  
 719 Figure 4A, the vaccinated branch can be separated into partially and fully vaccinated sub-branches. Shown here  
 720 assuming protection against infection,  $E_i = 0$ , and protection against symptoms for fully vaccinated individuals  $E_s$   
 721 is greater than the mean protection against symptoms for partially vaccinated individuals  $E_{\text{partial}}$ . Bottom: The percent  
 722 reduction in the number of expected symptomatic infections across a range of partial vaccination rates with partial  
 723 vaccine efficacy. Two example scenarios are shown where 50% of the targeted population is fully vaccinated and 0-  
 724 50% of the population is partially vaccinated with protection varying from 0 to equaling the efficacy seen in fully  
 725 vaccinated individuals ( $E_s$ ). The shaded area shows the scenarios with sufficient efficacy and coverage to observe a  
 726 50% reduction in symptomatic infections.

727

728 **Figure S7. Sensitivity analyses for vaccination parameters**



729

730 For the targeted subpopulation (i.e., children), the number of symptomatic malaria infections averted by vaccination  
731 with efficacy against symptoms  $E_s$ . Rows show results for four levels of infection rates, expressed as the cumulative  
732 proportion of the population expected to be infected over the time interval considered. Columns show results for  
733 three values for the probability with which infections become symptomatic.

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755



756 **Data S1**

757 Tropical cyclones and related humanitarian disasters in Madagascar since 1980 (xlsx)

758 **Data S2**

759 Locality information for study sites in Mananjary district, Madagascar including site codes,  
760 administrative division names, and coordinates of midpoints (xlsx)

761 **Data S3**

762 Line list data of individual rapid diagnostic test (RDT) results and sample dates (csv)

763 **Data S4**

764 Tropical cyclone tracks data from IBTrACS (csv)

765 Accessed from: [https://www.ncei.noaa.gov/data/international-best-track-archive-for-climate-stewardship-  
766 ibtracs/v04r00/access/csv/](https://www.ncei.noaa.gov/data/international-best-track-archive-for-climate-stewardship-ibtracs/v04r00/access/csv/)

767 **Data S5**

768 Global estimates of average annual tropical cyclone exposure from Jing et al 2023 (39) (csv)

769 **Data S6**

770 Spatial estimates of *Plasmodium falciparum* incidence rate for 2020 from the Malaria Atlas  
771 Project (tif)

772 Accessed from: <https://data.malariaatlas.org/>

773 **Data S7**

774 National level estimated incidence of malaria from the World Health Organization (xlsx)

775 **Data S8**

776 Bednet usage questionnaire response data for the Mananjary cohort study (csv)

777 **Data S9**

778 Symptoms questionnaire response data for the Mananjary cohort study (csv)

779

780

781

782

783

## 784 **References and Notes:**

- 785 1. "World Malaria Report 2023" (Global Malaria Programme, World Health Organization,  
786 2023); <https://www.who.int/publications/i/item/9789240086173>.
- 787 2. J. R. Poespoprodjo, N. M. Douglas, D. Ansong, S. Kho, N. M. Anstey, Malaria. *Lancet* **402**,  
788 2328–2345 (2023).
- 789 3. E. A. Mordecai, J. M. Caldwell, M. K. Grossman, C. A. Lippi, L. R. Johnson, M. Neira, J. R.  
790 Rohr, S. J. Ryan, V. Savage, M. S. Shocket, R. Sippy, A. M. Stewart Ibarra, M. B. Thomas,  
791 O. Villena, Thermal biology of mosquito-borne disease. *Ecol. Lett.* **22**, 1690–1708 (2019).
- 792 4. O. C. Villena, S. J. Ryan, C. C. Murdock, L. R. Johnson, Temperature impacts the  
793 environmental suitability for malaria transmission by *Anopheles gambiae* and *Anopheles*  
794 *stephensi*. *Ecology* **103**, e3685 (2022).
- 795 5. W. M. de Souza, S. C. Weaver, Effects of climate change and human activities on vector-  
796 borne diseases. *Nat. Rev. Microbiol.*, doi: 10.1038/s41579-024-01026-0 (2024).
- 797 6. E. A. Mordecai, K. P. Paaijmans, L. R. Johnson, C. Balzer, T. Ben-Horin, E. de Moor, A.  
798 McNally, S. Pawar, S. J. Ryan, T. C. Smith, K. D. Lafferty, Optimal temperature for malaria  
799 transmission is dramatically lower than previously predicted. *Ecol. Lett.* **16**, 22–30 (2013).
- 800 7. K. P. Paaijmans, A. F. Read, M. B. Thomas, Understanding the link between malaria risk  
801 and climate. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 13844–13849 (2009).
- 802 8. S. J. Ryan, C. A. Lippi, F. Zermoglio, Shifting transmission risk for malaria in Africa with  
803 climate change: a framework for planning and intervention. *Malar. J.* **19**, 170 (2020).
- 804 9. A. S. Siraj, M. Santos-Vega, M. J. Bouma, D. Yadeta, D. Ruiz Carrascal, M. Pascual,  
805 Altitudinal changes in malaria incidence in highlands of Ethiopia and Colombia. *Science*  
806 **343**, 1154–1158 (2014).
- 807 10. C. Caminade, S. Kovats, J. Rocklöv, A. M. Tompkins, A. P. Morse, F. J. Colón-González,  
808 H. Stenlund, P. Martens, S. J. Lloyd, Impact of climate change on global malaria  
809 distribution. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 3286–3291 (2014).
- 810 11. K. T. Bhatia, G. A. Vecchi, T. R. Knutson, H. Murakami, J. Kossin, K. W. Dixon, C. E.  
811 Whitlock, Recent increases in tropical cyclone intensification rates. *Nat. Commun.* **10**, 635  
812 (2019).
- 813 12. J. B. Elsner, J. P. Kossin, T. H. Jagger, The increasing intensity of the strongest tropical  
814 cyclones. *Nature* **455**, 92–95 (2008).
- 815 13. L. Li, P. Chakraborty, Slower decay of landfalling hurricanes in a warming world. *Nature*  
816 **587**, 230–234 (2020).
- 817 14. S. Wang, R. Toumi, Recent migration of tropical cyclones toward coasts. *Science* **371**,  
818 514–517 (2021).
- 819 15. A. M. D. Ortiz, P. L. C. Chua, D. Salvador Jr, C. Dyngeland, J. D. G. Albao Jr, R. A.  
820 Abesamis, Impacts of tropical cyclones on food security, health and biodiversity. *Bull. World*

- 821 *Health Organ.* **101**, 152–154 (2023).
- 822 16. J. M. Shultz, J. Russell, Z. Espinel, Epidemiology of tropical cyclones: the dynamics of  
823 disaster, disease, and development. *Epidemiol. Rev.* **27**, 21–35 (2005).
- 824 17. R. M. Parks, G. B. Anderson, R. C. Nethery, A. Navas-Acien, F. Dominici, M.-A.  
825 Kioumourtzoglou, Tropical cyclone exposure is associated with increased hospitalization  
826 rates in older adults. *Nat. Commun.* **12**, 1545 (2021).
- 827 18. T. Alcayna, I. Fletcher, R. Gibb, L. Tremblay, S. Funk, B. Rao, R. Lowe, Climate-sensitive  
828 disease outbreaks in the aftermath of extreme climatic events: A scoping review. *One Earth*  
829 **5**, 336–350 (2022).
- 830 19. K. L. Ebi, J. Vanos, J. W. Baldwin, J. E. Bell, D. M. Hondula, N. A. Errett, K. Hayes, C. E.  
831 Reid, S. Saha, J. Spector, P. Berry, Extreme Weather and Climate Change: Population  
832 Health and Health System Implications. *Annu. Rev. Public Health* **42**, 293–315 (2021).
- 833 20. H. Nissan, I. Ukawuba, M. Thomson, Climate-proofing a malaria eradication strategy.  
834 *Malar. J.* **20**, 190 (2021).
- 835 21. K. M. Searle, D. E. Earland, A. Francisco Bibe, A. Novela, V. Muhiro, J. L. Ferrão, Long-  
836 lasting household damage from Cyclone Idai increases malaria risk in rural western  
837 Mozambique. *Sci. Rep.* **13**, 21590 (2023).
- 838 22. S. Devi, Cyclone Idai: 1 month later, devastation persists. *Lancet* **393**, 1585 (2019).
- 839 23. A. Pozniak, A. Atzori, C. Marotta, F. Di Gennaro, G. Putoto, HIV continuity of care after  
840 Cyclone Idai in Mozambique. *Lancet HIV* **7**, e159–e160 (2020).
- 841 24. Q. Fernandes, O. Augusto, S. Chicumbe, L. Anselmi, B. H. Wagenaar, R. Marlene, S.  
842 Agostinho, S. Gimbel, J. Pfeiffer, C. Inguane, D. M. Uetela, J. Crocker, I. Ramiro, B.  
843 Matsinhe, S. Tembe, N. Carimo, S. Gloyd, I. Manhiça, E. Tavede, P. Felimone, K. Sherr,  
844 Maternal and Child Health Care Service Disruptions and Recovery in Mozambique After  
845 Cyclone Idai: An Uncontrolled Interrupted Time Series Analysis. *Glob Health Sci Pract* **10**  
846 (2022).
- 847 25. J. E. Coalson, E. J. Anderson, E. M. Santos, V. Madera Garcia, J. K. Romine, B.  
848 Dominguez, D. M. Richard, A. C. Little, M. H. Hayden, K. C. Ernst, The Complex  
849 Epidemiological Relationship between Flooding Events and Human Outbreaks of Mosquito-  
850 Borne Diseases: A Scoping Review. *Environ. Health Perspect.* **129**, 96002 (2021).
- 851 26. J. T. Watson, M. Gayer, M. A. Connolly, Epidemics after natural disasters. *Emerg. Infect.*  
852 *Dis.* **13**, 1–5 (2007).
- 853 27. IPCC, *Climate Change 2021: The Physical Science Basis. Contribution of Working Group I*  
854 *to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change*  
855 (Cambridge University Press, Cambridge, United Kingdom and New York, NY, USA, 2021).
- 856 28. J. P. Kossin, K. R. Knapp, T. L. Olander, C. S. Velden, Global increase in major tropical  
857 cyclone exceedance probability over the past four decades. *Proc. Natl. Acad. Sci. U. S. A.*  
858 **117**, 11975–11980 (2020).
- 859 29. “Cyclone Freddy deepens health risks in worst-hit countries” (World Health Organization

- 860 (WHO) African Region, 2023); [https://www.afro.who.int/news/cyclone-freddy-deepens-](https://www.afro.who.int/news/cyclone-freddy-deepens-health-risks-worst-hit-countries)  
861 [health-risks-worst-hit-countries](https://www.afro.who.int/news/cyclone-freddy-deepens-health-risks-worst-hit-countries).
- 862 30. “Mobilizing health assistance after deadly cyclones devastate Madagascar” (World Health  
863 Organization (WHO) African Region, 2022); [https://www.afro.who.int/photo-story/mobilizing-](https://www.afro.who.int/photo-story/mobilizing-health-assistance-after-deadly-cyclones-devastate-madagascar)  
864 [health-assistance-after-deadly-cyclones-devastate-madagascar](https://www.afro.who.int/photo-story/mobilizing-health-assistance-after-deadly-cyclones-devastate-madagascar).
- 865 31. “In Madagascar, mobile clinics bolster health surveillance during cyclones” (World Health  
866 Organization (WHO) Regional Office for Africa, 2023);  
867 [https://www.afro.who.int/countries/madagascar/news/madagascar-mobile-clinics-bolster-](https://www.afro.who.int/countries/madagascar/news/madagascar-mobile-clinics-bolster-health-surveillance-during-cyclones)  
868 [health-surveillance-during-cyclones](https://www.afro.who.int/countries/madagascar/news/madagascar-mobile-clinics-bolster-health-surveillance-during-cyclones).
- 869 32. “Outbreaks and emergencies bulletin, week 12: 13 - 19 march 2023: Cyclone Freddy in the  
870 WHO African Region” (12, World Health Organization (WHO) African Region, 2023);  
871 [https://www.afro.who.int/countries/togo/publication/outbreaks-and-emergencies-bulletin-](https://www.afro.who.int/countries/togo/publication/outbreaks-and-emergencies-bulletin-week-12-13-19-march-2023)  
872 [week-12-13-19-march-2023](https://www.afro.who.int/countries/togo/publication/outbreaks-and-emergencies-bulletin-week-12-13-19-march-2023).
- 873 33. D. Delforge, V. Wathelet, R. Below, C. L. Sofia, M. Tonnelier, J. van Loenhout, N.  
874 Speybroeck, EM-DAT: The Emergency Events Database, *Research Square* (2023).  
875 <https://doi.org/10.21203/rs.3.rs-3807553/v1>.
- 876 34. FEL Otto, M Zachariah, P Wolski, I Pinto, R Barimalala, B Nhamtumbo, R Bonnet, R  
877 Vautard, S Philip, S Kew, LN Luu, D Heinrich, M Vahlberg, R Singh, J Arrighi, L  
878 Thalheimer, Mv Aalst, S Li, J Sun, G Vecchi, LJ Harrington, “Climate change increased  
879 rainfall associated with tropical cyclones hitting highly vulnerable communities in  
880 Madagascar, Mozambique & Malawi” (World Weather Attribution (WWA) Initiative, 2022);  
881 [https://www.worldweatherattribution.org/climate-change-increased-rainfall-associated-with-](https://www.worldweatherattribution.org/climate-change-increased-rainfall-associated-with-tropical-cyclones-hitting-highly-vulnerable-communities-in-madagascar-mozambique-malawi/)  
882 [tropical-cyclones-hitting-highly-vulnerable-communities-in-madagascar-mozambique-](https://www.worldweatherattribution.org/climate-change-increased-rainfall-associated-with-tropical-cyclones-hitting-highly-vulnerable-communities-in-madagascar-mozambique-malawi/)  
883 [malawi/](https://www.worldweatherattribution.org/climate-change-increased-rainfall-associated-with-tropical-cyclones-hitting-highly-vulnerable-communities-in-madagascar-mozambique-malawi/).
- 884 35. K. R. Knapp, M. C. Kruk, D. H. Levinson, H. J. Diamond, C. J. Neumann, The International  
885 Best Track Archive for Climate Stewardship (IBTrACS): Unifying Tropical Cyclone Data.  
886 *Bull. Am. Meteorol. Soc.* **91**, 363–376 (2010).
- 887 36. K. R. Knapp, H. J. Diamond, J. P. Kossin, M. C. Kruk, C. J. Schreck, International best  
888 track archive for climate stewardship (IBTrACS) project, version 4, NOAA National Centers  
889 for Environmental Information (2018); <https://doi.org/10.25921/82TY-9E16>.
- 890 37. D. A. Pfeffer, T. C. D. Lucas, D. May, J. Harris, J. Rozier, K. A. Twohig, U. Dalrymple, C. A.  
891 Guerra, C. L. Moyes, M. Thorn, M. Nguyen, S. Bhatt, E. Cameron, D. J. Weiss, R. E.  
892 Howes, K. E. Battle, H. S. Gibson, P. W. Gething, malariaAtlas: an R interface to global  
893 malariometric data hosted by the Malaria Atlas Project. *Malar. J.* **17**, 352 (2018).
- 894 38. C. P. T. G. Zehr, *Biscale: Tools and Palettes for Bivariate Thematic Mapping R Package*  
895 (2022; <https://chris-prener.github.io/biscale/authors.html>).
- 896 39. R. Jing, S. Heft-Neal, D. R. Chavas, M. Griswold, Z. Wang, A. Clark-Ginsberg, D. Guha-  
897 Sapir, E. Bendavid, Z. Wagner, Global population profile of tropical cyclone exposure from  
898 2002 to 2019. *Nature* **626**, 549–554 (2024).
- 899 40. The Global Health Observatory, World Health Organization, Malaria incidence per 1 000  
900 population at risk per year (estimated) - By country, World Health Organization (2023);

- 901 <https://apps.who.int/gho/data/node.main.MALARIAESTINCIDENCE?lang=en>.
- 902 41. H. C. Slater, A. Ross, I. Felger, N. E. Hofmann, L. Robinson, J. Cook, B. P. Gonçalves, A.  
903 Björkman, A. L. Ouedraogo, U. Morris, M. Msellem, C. Koepfli, I. Mueller, F. Tadesse, E.  
904 Gadisa, S. Das, G. Domingo, M. Kapulu, J. Midega, S. Owusu-Agyei, C. Nabet, R.  
905 Piarroux, O. Doumbo, S. N. Doumbo, K. Koram, N. Lucchi, V. Udhayakumar, J. Mosha, A.  
906 Tiono, D. Chandramohan, R. Gosling, F. Mwingira, R. Sauerwein, R. Paul, E. M. Riley, N.  
907 J. White, F. Nosten, M. Imwong, T. Bousema, C. Drakeley, L. C. Okell, The temporal  
908 dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to  
909 parasite density. *Nat. Commun.* **10**, 1433 (2019).
- 910 42. E. A. Ashley, N. J. White, The duration of Plasmodium falciparum infections. *Malar. J.* **13**,  
911 500 (2014).
- 912 43. European Space Agency, Sinergise, OpenTopography - Copernicus global digital elevation  
913 models, (2021); <https://doi.org/10.5069/G9028PQB>.
- 914 44. B. L. Rice, C. D. Golden, H. J. Randriamady, A. A. N. A. Rakotomalala, M. A. Vonona, E. J.  
915 G. Anjaranirina, J. Hazen, M. C. Castro, C. J. E. Metcalf, D. L. Hartl, Fine-scale variation in  
916 malaria prevalence across ecological regions in Madagascar: a cross-sectional study. *BMC*  
917 *Public Health* **21**, 1018 (2021).
- 918 45. “U.S. President’s Malaria Initiative Madagascar Malaria Operational Plan FY 2023”  
919 (President’s Malaria Initiative, 2023); [https://www.pmi.gov/resources/malaria-operational-](https://www.pmi.gov/resources/malaria-operational-plans-mops/)  
920 [plans-mops/](https://www.pmi.gov/resources/malaria-operational-plans-mops/).
- 921 46. M. T. Bretscher, P. Dahal, J. Griffin, K. Stepniewska, Q. Bassat, E. Baudin, U.  
922 D’Alessandro, A. A. Djimde, G. Dorsey, E. Espié, B. Fofana, R. González, E. Juma, C.  
923 Karema, E. Lasry, B. Lell, N. Lima, C. Menéndez, G. Mombo-Ngoma, C. Moreira, F.  
924 Nikiema, J. B. Ouédraogo, S. G. Staedke, H. Tinto, I. Valea, A. Yeka, A. C. Ghani, P. J.  
925 Guerin, L. C. Okell, The duration of chemoprophylaxis against malaria after treatment with  
926 artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and  
927 pfcr1 76T: a meta-analysis of individual patient data. *BMC Med.* **18**, 47 (2020).
- 928 47. M. Cairns, I. Carneiro, P. Milligan, S. Owusu-Agyei, T. Awine, R. Gosling, B. Greenwood,  
929 D. Chandramohan, Duration of protection against malaria and anaemia provided by  
930 intermittent preventive treatment in infants in Navrongo, Ghana. *PLoS One* **3**, e2227  
931 (2008).
- 932 48. M. Cairns, A. Barry, I. Zongo, I. Sagara, S. R. Yerbanga, M. Diarra, C. Zoungrana, D.  
933 Issiaka, A. A. Sienou, A. Tapily, K. Sanogo, M. Kaya, S. Traore, K. Diarra, H. Yalcouye, Y.  
934 Sidibe, A. Haro, I. Thera, P. Snell, J. Grant, H. Tinto, P. Milligan, D. Chandramohan, B.  
935 Greenwood, A. Dicko, J. B. Ouedraogo, The duration of protection against clinical malaria  
936 provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria  
937 chemoprevention versus either intervention given alone. *BMC Med.* **20**, 352 (2022).
- 938 49. RTS,S Clinical Trials Partnership, S. T. Agnandji, B. Lell, S. S. Soulanoudjingar, J. F.  
939 Fernandes, B. P. Abossolo, C. Conzelmann, B. G. N. O. Methogo, Y. Doucka, A. Flamen,  
940 B. Mordmüller, S. Issifou, P. G. Kremsner, J. Sacarlal, P. Aide, M. Lanassa, J. J. Aponte, A.  
941 Nhamuave, D. Quelhas, Q. Bassat, S. Mandjate, E. Macete, P. Alonso, S. Abdulla, N.  
942 Salim, O. Juma, M. Shomari, K. Shubis, F. Machera, A. S. Hamad, R. Minja, A. Mtoro, A.  
943 Sykes, S. Ahmed, A. M. Urassa, A. M. Ali, G. Mwangoka, M. Tanner, H. Tinto, U.



- 944 D'Alessandro, H. Sorgho, I. Valea, M. C. Tahita, W. Kaboré, S. Ouédraogo, Y. Sandrine, R.  
945 T. Guiguemdé, J. B. Ouédraogo, M. J. Hamel, S. Kariuki, C. Odero, M. Oneko, K. Otieno,  
946 N. Awino, J. Omoto, J. Williamson, V. Muturi-Kioi, K. F. Laserson, L. Slutsker, W. Otieno, L.  
947 Otieno, O. Nekoye, S. Gondi, A. Otieno, B. Ogutu, R. Wasuna, V. Owira, D. Jones, A. A.  
948 Onyango, P. Njuguna, R. Chilengi, P. Akoo, C. Kerubo, J. Gitaka, C. Maingi, T. Lang, A.  
949 Olotu, B. Tsofa, P. Bejon, N. Peshu, K. Marsh, S. Owusu-Agyei, K. P. Asante, K. Osei-  
950 Kwakye, O. Boahen, S. Ayamba, K. Kayan, R. Owusu-Ofori, D. Dosoo, I. Asante, G. Adjei,  
951 G. Adjei, D. Chandramohan, B. Greenwood, J. Lusingu, S. Gesase, A. Malabeja, O. Abdul,  
952 H. Kilavo, C. Mahende, E. Liheluka, M. Lemnge, T. Theander, C. Drakeley, D. Ansong, T.  
953 Agbenyega, S. Adjei, H. O. Boateng, T. Rettig, J. Bawa, J. Sylverken, D. Sambian, A.  
954 Agyekum, L. Owusu, F. Martinson, I. Hoffman, T. Mvalo, P. Kamthunzi, R. Nkomo, A.  
955 Msika, A. Jumbe, N. Chome, D. Nyakuipa, J. Chintedza, W. R. Ballou, M. Bruls, J. Cohen,  
956 Y. Guerra, E. Jongert, D. Lapierre, A. Leach, M. Lievens, O. Ofori-Anyinam, J. Vekemans,  
957 T. Carter, D. Leboulleux, C. Loucq, A. Radford, B. Savarese, D. Schellenberg, M. Sillman,  
958 P. Vansadia, First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African  
959 children. *N. Engl. J. Med.* **365**, 1863–1875 (2011).
- 960 50. M. S. Dattoo, A. Dicko, H. Tinto, J.-B. Ouédraogo, M. Hamaluba, A. Olotu, E. Beaumont, F.  
961 Ramos Lopez, H. M. Natama, S. Weston, M. Chemba, Y. D. Compaore, D. Issiaka, D.  
962 Salou, A. M. Some, S. Omenda, A. Lawrie, P. Bejon, H. Rao, D. Chandramohan, R.  
963 Roberts, S. Bharati, L. Stockdale, S. Gairola, B. M. Greenwood, K. J. Ewer, J. Bradley, P.  
964 S. Kulkarni, U. Shaligram, A. V. S. Hill, R21/Matrix-M Phase 3 Trial Group, Safety and  
965 efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre,  
966 double-blind, randomised, phase 3 trial. *Lancet* **403**, 533–544 (2024).
- 967 51. T. Bousema, L. Okell, I. Felger, C. Drakeley, Asymptomatic malaria infections: detectability,  
968 transmissibility and public health relevance. *Nat. Rev. Microbiol.* **12**, 833–840 (2014).
- 969 52. E. Rajaonarifara, M. H. Bonds, A. C. Miller, F. A. Ihantamalala, L. Cordier, B. Razafinjato,  
970 F. H. Rafenoarimalala, K. E. Finnegan, R. J. L. Rakotonanahary, G. Cowley, B.  
971 Ratsimbazafy, F. Razafimamonjy, M. Randriamanambintsoa, E. M. Raza-  
972 Fanomezananahary, A. Randrianambinina, C. J. Metcalf, B. Roche, A. Garchitorea,  
973 Impact of health system strengthening on delivery strategies to improve child immunisation  
974 coverage and inequalities in rural Madagascar. *BMJ Glob Health* **7** (2022).
- 975 53. F. K. Jones, K. Mensah, J.-M. Heraud, F. M. Randriatsarafara, C. J. E. Metcalf, A.  
976 Wesolowski, The Challenge of Achieving Immunity Through Multiple-Dose Vaccines in  
977 Madagascar. *Am. J. Epidemiol.* **190**, 2085–2093 (2021).
- 978 54. M. S. Dattoo, H. M. Natama, A. Somé, D. Bellamy, O. Traoré, T. Rouamba, M. C. Tahita, N.  
979 F. A. Ido, P. Yameogo, D. Valia, A. Millogo, F. Ouedraogo, R. Soma, S. Sawadogo, F.  
980 Sorgho, K. Derra, E. Rouamba, F. Ramos-Lopez, M. Cairns, S. Provstgaard-Morys, J.  
981 Aboagye, A. Lawrie, R. Roberts, I. Valéa, H. Sorgho, N. Williams, G. Glenn, L. Fries, J.  
982 Reimer, K. J. Ewer, U. Shaligram, A. V. S. Hill, H. Tinto, Efficacy and immunogenicity of  
983 R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina  
984 Faso: a phase 1/2b randomised controlled trial. *Lancet Infect. Dis.* **22**, 1728–1736 (2022).
- 985 55. Institut National de la Statistique (INSTAT) et ICF, *Enquête Démographique et de Santé à*  
986 *Madagascar (EDSMD-V) 2021* (2022).
- 987 56. Intergovernmental Panel on Climate Change (IPCC), "Weather and Climate Extreme  
988 Events in a Changing Climate" in *Climate Change 2021 – The Physical Science Basis*:



- 989 *Working Group I Contribution to the Sixth Assessment Report of the Intergovernmental*  
990 *Panel on Climate Change* (Cambridge University Press, 2023), pp. 1513–1766.
- 991 57. H. C. Slater, A. Ross, A. L. Ouédraogo, L. J. White, C. Nguon, P. G. T. Walker, P. Ngor, R.  
992 Aguas, S. P. Silal, A. M. Dondorp, P. La Barre, R. Burton, R. W. Sauerwein, C. Drakeley, T.  
993 A. Smith, T. Bousema, A. C. Ghani, Assessing the impact of next-generation rapid  
994 diagnostic tests on Plasmodium falciparum malaria elimination strategies. *Nature* **528**,  
995 S94–101 (2015).
- 996 58. L. Wu, L. L. van den Hoogen, H. Slater, P. G. T. Walker, A. C. Ghani, C. J. Drakeley, L. C.  
997 Okell, Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum  
998 infections to inform control and elimination strategies. *Nature* **528**, S86–93 (2015).
- 999 59. J. T. Lin, D. L. Saunders, S. R. Meshnick, The role of submicroscopic parasitemia in  
1000 malaria transmission: what is the evidence? *Trends Parasitol.* **30**, 183–190 (2014).
- 1001 60. “WHO guidelines for malaria” (World Health Organization, Geneva, 2023);  
1002 <https://www.ncbi.nlm.nih.gov/pubmed/36580567>.
- 1003 61. N. Schmit, H. M. Topazian, H. M. Natama, D. Bellamy, O. Traoré, M. A. Somé, T.  
1004 Rouamba, M. C. Tahita, M. D. A. Bonko, A. Sourabié, H. Sorgho, L. Stockdale, S.  
1005 Provstgaard-Morys, J. Aboagye, D. Woods, K. Rapi, M. S. Dattoo, F. R. Lopez, G. D.  
1006 Charles, K. McCain, J.-B. Ouedraogo, M. Hamaluba, A. Olotu, A. Dicko, H. Tinto, A. V. S.  
1007 Hill, K. J. Ewer, A. C. Ghani, P. Winskill, The public health impact and cost-effectiveness of  
1008 the R21/Matrix-M malaria vaccine: a mathematical modelling study. *Lancet Infect. Dis.*, doi:  
1009 10.1016/S1473-3099(23)00816-2 (2024).
- 1010 62. H. M. Topazian, N. Schmit, I. Gerard-Ursin, G. D. Charles, H. Thompson, A. C. Ghani, P.  
1011 Winskill, Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine  
1012 compared to investment in vector control or chemoprophylaxis. *Vaccine* **41**, 3215–3223  
1013 (2023).
- 1014 63. O. O. Adeshina, S. Nyame, J. Milner, A. Milojevic, K. P. Asante, Barriers and facilitators to  
1015 nationwide implementation of the malaria vaccine in Ghana. *Health Policy Plan.* **38**, 28–37  
1016 (2023).
- 1017 64. World Health Organization, *Malaria Control in Humanitarian Emergencies: An Inter-Agency*  
1018 *Field Handbook* (World Health Organization, 2013).
- 1019 65. M. Burns, M. Rowland, R. N’Guessan, I. Carneiro, A. Beeche, S. S. Ruiz, S. Kamara, W.  
1020 Takken, P. Carnevale, R. Allan, Insecticide-treated plastic sheeting for emergency malaria  
1021 prevention and shelter among displaced populations: an observational cohort study in a  
1022 refugee setting in Sierra Leone. *Am. J. Trop. Med. Hyg.* **87**, 242–250 (2012).
- 1023 66. L. A. Messenger, J. Furnival-Adams, B. Pelloquin, M. Rowland, Vector control for malaria  
1024 prevention during humanitarian emergencies: protocol for a systematic review and meta-  
1025 analysis. *BMJ Open* **11**, e046325 (2021).
- 1026 67. World Health Organization, *Operational Framework for Building Climate Resilient Health*  
1027 *Systems* (World Health Organization, Genève, Switzerland, 2015).
- 1028 68. M. Romanello, A. McGushin, C. Di Napoli, P. Drummond, N. Hughes, L. Jamart, H.

- 1029 Kennard, P. Lampard, B. Solano Rodriguez, N. Arnell, S. Ayeb-Karlsson, K. Belesova, W.  
1030 Cai, D. Campbell-Lendrum, S. Capstick, J. Chambers, L. Chu, L. Ciampi, C. Dalin, N.  
1031 Dasandi, S. Dasgupta, M. Davies, P. Dominguez-Salas, R. Dubrow, K. L. Ebi, M.  
1032 Eckelman, P. Ekins, L. E. Escobar, L. Georgeson, D. Grace, H. Graham, S. H. Gunther, S.  
1033 Hartinger, K. He, C. Heaviside, J. Hess, S.-C. Hsu, S. Jankin, M. P. Jimenez, I. Kelman, G.  
1034 Kiesewetter, P. L. Kinney, T. Kjellstrom, D. Kniveton, J. K. W. Lee, B. Lemke, Y. Liu, Z. Liu,  
1035 M. Lott, R. Lowe, J. Martinez-Urtaza, M. Maslin, L. McAllister, C. McMichael, Z. Mi, J.  
1036 Milner, K. Minor, N. Mohajeri, M. Moradi-Lakeh, K. Morrissey, S. Munzert, K. A. Murray, T.  
1037 Neville, M. Nilsson, N. Obradovich, M. O. Sewe, T. Oreszczyn, M. Otto, F. Owfi, O.  
1038 Pearman, D. Pencheon, M. Rabbaniha, E. Robinson, J. Rocklöv, R. N. Salas, J. C.  
1039 Semenza, J. Sherman, L. Shi, M. Springmann, M. Tabatabaei, J. Taylor, J. Trinanes, J.  
1040 Shumake-Guillemot, B. Vu, F. Wagner, P. Wilkinson, M. Winning, M. Yglesias, S. Zhang, P.  
1041 Gong, H. Montgomery, A. Costello, I. Hamilton, The 2021 report of the Lancet Countdown  
1042 on health and climate change: code red for a healthy future. *Lancet* **398**, 1619–1662  
1043 (2021).
- 1044 69. M. E. Beatty, E. Hunsperger, E. Long, J. Schürch, S. Jain, R. Colindres, G. Lerebours, Y.-  
1045 M. Bernard, J. G. Dobbins, M. Brown, G. G. Clark, Mosquitoborne infections after Hurricane  
1046 Jeanne, Haiti, 2004. *Emerg. Infect. Dis.* **13**, 308–310 (2007).
- 1047 70. T. Fürst, G. Raso, C. A. Acka, A. B. Tschannen, E. K. N’Goran, J. Utzinger, Dynamics of  
1048 socioeconomic risk factors for neglected tropical diseases and malaria in an armed conflict.  
1049 *PLoS Negl. Trop. Dis.* **3**, e513 (2009).
- 1050 71. L. Sedda, Q. Qi, A. J. Tatem, A geostatistical analysis of the association between armed  
1051 conflicts and Plasmodium falciparum malaria in Africa, 1997-2010. *Malar. J.* **14**, 500 (2015).
- 1052 72. M. A. Connolly, M. Gayer, M. J. Ryan, P. Salama, P. Spiegel, D. L. Heymann,  
1053 Communicable diseases in complex emergencies: impact and challenges. *Lancet* **364**,  
1054 1974–1983 (2004).
- 1055 73. {Institut National de la Statistique-INSTAT/Madagascar, Programme National de lutte  
1056 contre le Paludisme-PNLP/Madagascar, Institut Pasteur de Madagascar -  
1057 IPM/Madagascar, and ICF International, *Enquête Sur Les Indicateurs Du Paludisme 2016*  
1058 *Madagascar* (Calverton, MD, USA : INSTAT, PNLP, IPM and ICF International., 2017).
- 1059 74. Institut National de la Statistique-INSTAT/Madagascar, Programme National de lutte contre  
1060 le Paludisme-PNLP/Madagascar, Institut Pasteur de Madagascar-IPM/Madagascar, ICF  
1061 International, *Madagascar Enquête Sur Les Indicateurs Du Paludisme (EIPM) 2013* (2013).
- 1062 75. Institut National de la Statistique/Madagascar, Programme National de Lutte contre le  
1063 Paludisme/Madagascar, ICF International, Madagascar Enquête sur les Indicateurs du  
1064 Paludisme à Madagascar (EIPMD) 2011. (2012).
- 1065 76. R. Arambepola, S. H. Keddie, E. L. Collins, K. A. Twohig, P. Amratia, A. Bertozzi-Villa, E.  
1066 G. Chestnutt, J. Harris, J. Millar, J. Rozier, S. F. Rumisha, T. L. Symons, C. Vargas-Ruiz,  
1067 M. Andriamananjara, S. Rabehisoa, A. C. Ratsimbaoa, R. E. Howes, D. J. Weiss, P. W.  
1068 Gething, E. Cameron, Spatiotemporal mapping of malaria prevalence in Madagascar using  
1069 routine surveillance and health survey data. *Sci. Rep.* **10**, 18129 (2020).
- 1070 77. R. E. Howes, S. A. Mioramalala, B. Ramiranirina, T. Franchard, A. J. Rakotorahalahy, D.  
1071 Bisanzio, P. W. Gething, P. A. Zimmerman, A. Ratsimbaoa, Contemporary

- 1072 epidemiological overview of malaria in Madagascar: operational utility of reported routine  
1073 case data for malaria control planning. *Malar. J.* **15**, 502 (2016).
- 1074 78. M. Nguyen, R. E. Howes, T. C. D. Lucas, K. E. Battle, E. Cameron, H. S. Gibson, J. Rozier,  
1075 S. Keddie, E. Collins, R. Arambepola, S. Y. Kang, C. Hendriks, A. Nandi, S. F. Rumisha, S.  
1076 Bhatt, S. A. Mioramalala, M. A. Nambinisoa, F. Rakotomanana, P. W. Gething, D. J. Weiss,  
1077 Mapping malaria seasonality in Madagascar using health facility data. *BMC Med.* **18**, 26  
1078 (2020).
- 1079 79. R. Ratovoson, A. Garchitorena, D. Kassie, J. A. Ravelonarivo, V. Andrianaranjaka, S.  
1080 Razanatsiorimalala, A. Razafimandimby, F. Rakotomanana, L. Ohlstein, R.  
1081 Mangahasimbola, S. A. N. Randrianirisoa, J. Razafindrakoto, C. M. Dentinger, J.  
1082 Williamson, L. Kapesa, P. Piola, M. Randrianariveლოსია, J. Thwing, L. C. Steinhardt, L.  
1083 Baril, Proactive community case management decreased malaria prevalence in rural  
1084 Madagascar: results from a cluster randomized trial. *BMC Med.* **20**, 322 (2022).
- 1085 80. C. D. Golden, E. J. G. Anjaranirina, L. C. H. Fernald, D. L. Hartl, C. Kremen, D. A. Milner Jr,  
1086 D. H. Ralalason, H. Ramihantaniarivo, H. Randriamady, B. L. Rice, B. Vaitla, S. K.  
1087 Volkman, M. A. Vonona, S. S. Myers, Cohort Profile: The Madagascar Health and  
1088 Environmental Research (MAHERY) study in north-eastern Madagascar. *Int. J. Epidemiol.*  
1089 **46**, 1747–1748d (2017).
- 1090 81. C. D. Golden, B. L. Rice, H. J. Randriamady, A. M. Vonona, J. F. Randrianasolo, A. N.  
1091 Tafangy, M. Y. Andrianantenaina, N. J. Arisco, G. N. Emile, F. Lainandrasana, R. F. F.  
1092 Mahonjolaza, H. P. Raelson, V. R. Rakotoarilalao, A. A. N. A. Rakotomalala, A. D.  
1093 Rasamison, R. Mahery, M. L. Tantely, R. Girod, A. Annapragada, A. Wesolowski, A.  
1094 Winter, D. L. Hartl, J. Hazen, C. J. E. Metcalf, Study Protocol: A Cross-Sectional  
1095 Examination of Socio-Demographic and Ecological Determinants of Nutrition and Disease  
1096 Across Madagascar. *Front Public Health* **8**, 500 (2020).
- 1097 82. B. L. Rice, C. D. Golden, E. J. G. Anjaranirina, C. M. Botelho, S. K. Volkman, D. L. Hartl,  
1098 Genetic evidence that the Makira region in northeastern Madagascar is a hotspot of malaria  
1099 transmission. *Malar. J.* **15**, 596 (2016).
- 1100 83. S. Xiaodong, E. Tambo, W. Chun, C. Zhibin, D. Yan, W. Jian, W. Jiazhi, Z. Xiaonong,  
1101 Diagnostic performance of CareStart™ malaria HRP2/pLDH (Pf/pan) combo test versus  
1102 standard microscopy on falciparum and vivax malaria between China-Myanmar endemic  
1103 borders. *Malar. J.* **12**, 6 (2013).
- 1104 84. G. M. Bwire, B. Ngasala, M. Kilonzi, W. P. Mikomangwa, F. F. Felician, A. A. R.  
1105 Kamuhabwa, Diagnostic performance of CareStart™ malaria HRP2/pLDH test in  
1106 comparison with standard microscopy for detection of uncomplicated malaria infection  
1107 among symptomatic patients, Eastern Coast of Tanzania. *Malar. J.* **18**, 354 (2019).
- 1108 85. D. A. Griffiths, A Catalytic Model of Infection for Measles. *J. R. Stat. Soc. Ser. C Appl. Stat.*  
1109 **23**, 330–339 (1974).
- 1110 86. N. Hens, Z. Shkedy, M. Aerts, C. Faes, P. Van Damme, P. Beutels, *Modeling Infectious*  
1111 *Disease Parameters Based on Serological and Social Contact Data* (Springer New York).
- 1112 87. L. C. Okell, C. J. Drakeley, A. C. Ghani, T. Bousema, C. J. Sutherland, Reduction of  
1113 transmission from malaria patients by artemisinin combination therapies: a pooled analysis

- 1114 of six randomized trials. *Malar. J.* **7**, 125 (2008).
- 1115 88. M. S. Dattoo, A. Dicko, H. Tinto, J.-B. Ouédraogo, M. Hamaluba, A. Olotu, E. Beaumont, F.  
1116 Ramos-Lopez, H. Magloire Natama, S. Weston, M. Chemba, Y. D. Compaore, D. Issiaka,  
1117 D. Salou, S. Omenda, A. Lawrie, P. Bejon, D. Chandramohan, R. Roberts, S. Bharati, L.  
1118 Stockdale, B. Greenwood, K. Ewer, J. Bradley, C. S. Poonawalla, P. S. Kulkarni, U.  
1119 Shaligram, A. V. S. Hill, A Phase III Randomised Controlled Trial Evaluating the Malaria  
1120 Vaccine Candidate R21/Matrix-M™ in African Children (2023).  
1121 <https://doi.org/10.2139/ssrn.4584076>.